Brought to you by:
New study validates BEST-CLI trial results, ‘suggesting generalizability’
A new propensity-matched analysis of more than 1,100 lower extremity revascularization procedures carried out in patients with chronic limb-threatening ischemia (CLTI)—which aimed to help solve the puzzle of why the BEST-CLI trial did not lead to a pick-up in the…
R3 Vascular announces first patient treated in ELITE-BTK pivotal trial
R3 Vascular recently announced that the first patient in its ELITE-BTK pivotal trial has been treated by Brian DeRubertis, chief of vascular surgery at New York-Presbyterian and Weill Cornell Medicine in New York City. The trial evaluates R3 Vascular’s next-generation…
Redefining ‘optimal medical therapy’ for vascular patients
Vascular and endovascular surgeons are frequently the only specialists other than primary care involved in the longitudinal care of their patients afflicted with clinically active vascular disease. As such, while scrutinizing the longitudinal and periprocedural outcomes in their patients, involvement…
ACC.25: Semaglutide improves walk distance for PAD patients with diabetes
Semaglutide significantly improved maximal walking distance in people with symptomatic peripheral arterial disease (PAD) and type 2 diabetes in a trial designed to evaluate the use of a GLP-1 agonist to manage PAD. In addition to improvements in walking ability…
VOYAGE scholarship program for young vascular surgeons
Th e Society for Vascular Surgery (SVS) Foundation, in partnership with the SVS Young Surgeons Section, has launched the VOYAGE Scholarship Program. This initiative will provide $1,000 scholarships to assist early-career vascular surgeons during their formative years in the profession. The…
SVS leadership and membership integral to ‘far-reaching’ BEST-CLI trial
Support from the Society for Vascular Surgery (SVS) and, later, funding from the SVS Foundation were integral to the BEST-CLI trial, said one of the landmark trial’s leaders. BEST-CLI sought to determine the best revascularization treatment strategy—surgical or endovascular—for patients…
Intermittent Topical Wound Oxygen: ‘It needs to no longer be seen as late-stage therapy’
This advertorial is sponsored by AOTI. Two prominent vascular surgeons discuss a rising tide of evidence pointing toward benefits of adjunct use of cyclically pressurized Topical Wound Oxygen (TWO2) therapy in the treatment of vascular ulceration. The best way to…
Study demonstrates textbook outcomes occur less than a quarter of the time after CLTI revascularization
Textbook outcomes remain “very rare” after revascularization for chronic limb-threatening ischemia (CLTI), with the main driver being an enduring inability to attain complete wound healing and to return patients to their preoperative ambulatory status, according to the lead researcher behind…
BEST-CLI trial spline model analysis breaks new ground in assessing the impact of CKD severity on CLTI outcomes
A new analysis of the BEST-CLI trial has produced the first evidence-based glomerular filtration rate (eGFR) value—30 mL m2—as the cutoff below which patients with chronic limb-threatening ischemia (CLTI) experience significantly worse outcomes after revascularization regardless of the treatment modality…
Deep vein arterialization: Much remains to be learned but use poised to expand in patients with less severe ischemia
These remain early days for transcatheter arterialization of the deep veins (TADV) in the setting of patients with severe chronic limb-threatening ischemia (CLTI), says Daniel Clair, MD, one of the principal investigators in key clinical trials of the procedure, but…